About TRexBio
We believe breakthrough therapeutics for patients with inflammatory diseases are within reach. By targeting the underlying dysregulation that drives disease, our team is identifying and advancing a pipeline of medicines that have the potential to transform how we treat a range of inflammatory conditions.
We Are Decoding Human Tissue Biology to Create Revolutionary Therapeutics
Many current therapies rely on broad immunosuppression or focus on inhibiting individual inflammatory pathways. At TRexBio, we are fundamentally rethinking these approaches. Our goal is to develop biologics that address autoimmune and inflammatory disease where it occurs – in the tissue – with the potential to restore immune balance, support tissue repair, and provide durable, disease-modifying benefit.
Leadership
We are a team of experienced and passionate scientists, drug development experts, and industry leaders. We are committed to developing breakthrough medicines by decoding human tissue biology and believe we are well positioned to usher in breakthrough medicines with this approach.
Johnston Erwin
Chief Executive Officer
Laura Berner, JD, MBA
Chief Operating Officer
Brandon Hants, MBA
Chief Financial Officer
Ariella Kelman, MD
Chief Medical Officer
Ali Zarrin, PhD
Chief Scientific Officer
Matt Chrysler, MBA
Head of Portfolio & Alliance Management
Carolyn Gabus
Vice President, Clinical Operations
Michael Townsend, PhD
Head of Translational Medicine
Board of Directors
Travis Coy, MBA
Director
Johnston Erwin
Chairman of the Board
Carol G. Gallagher, PharmD
Lead Independent Director
Julie Gilmore, PhD
Director
Peter Hirth, PhD
Director
Joel S. Marcus, JD, CPA
Director
Mike Ross, PhD
Director